EcoDrugPlus

Proteasome 20s Subunit Alpha 8

Ensembl ID : ENSOMYG00000031952
Gene Symbol: PSMA8
1 Cross references
130 Possible Orthologues:

Proteasome 20s Subunit Alpha 8

Ensembl ID : ENSOMYG00000035075
Gene Symbol: PSMA8
1 Cross references
167 Possible Orthologues:

Proteasome 20s Subunit Beta 1

Ensembl ID : ENSOMYG00000041069
Gene Symbol: PSMB1
1 Cross references
210 Possible Orthologues:

Proteasome 20s Subunit Beta 2

Ensembl ID : ENSOMYG00000040345
Gene Symbol: PSMB2
2 Cross references
214 Possible Orthologues:

Proteasome 20s Subunit Beta 4

Ensembl ID : ENSOMYG00000017508
Gene Symbol: PSMB4
1 Cross references
207 Possible Orthologues:

Proteasome 20s Subunit Beta 5

Ensembl ID : ENSOMYG00000042074
Gene Symbol: PSMB5
1 Cross references
146 Possible Orthologues:

Proteasome 20s Subunit Beta 5

Ensembl ID : ENSOMYG00000028124
Gene Symbol: PSMB5
2 Cross references
190 Possible Orthologues:

Proteasome 20s Subunit Beta 7

Ensembl ID : ENSOMYG00000041766
Gene Symbol: PSMB7
1 Cross references
215 Possible Orthologues:

Proteasome 20s Subunit Beta 9a

Ensembl ID : ENSOMYG00000008548
Gene Symbol: PSMB9A
1 Cross references
200 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 2

Ensembl ID : ENSOMYG00000041830
Gene Symbol: PSMD2
1 Cross references
216 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 4b

Ensembl ID : ENSOMYG00000032932
Gene Symbol: PSMD4B
1 Cross references
218 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 4b

Ensembl ID : ENSOMYG00000002085
Gene Symbol: PSMD4B
1 Cross references
217 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).